extracranial arteriovenous malformations
Conditions
Interventions
bleomycin group:Intralesional Bleomycin Injection
Sponsors
Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. In line with the diagnostic criteria of ISSVA for early arteriovenous malformations (Schobinger stage Phase I/II) containing superficial lesions; 2. Having not accepted any therapy; 3. No drug contraindications of bleomycin, including allergy, pregnant or lactating; 4. Ability and willingness to sign an inform consent form after fully understanding the therapeutic and follow-up strategies.
Exclusion criteria
Exclusion criteria: 1. Aged above 70. 2. Insufficient pulmonary functions and hepatorenal functions. 3. Patients with fever or WBC less than 2500 / cubic millimeter. 4. The combined use of other anti-tumor drugs. 5. Serious underlying systemic disease requiring treatment until illness either completes therapy or achieves clinical stablility on therapy for at least 6 months before enrolled the study. The systemic diseases include insufficient pulmonary functions(COPD, pneumonia, pulmonary fibrosis and asthma), insufficient cardiac and hepatorenal functions, infection , hemorrhagic tendency, immunologic disease(SLE, urticaria, HIV).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Digital Subtraction Angiography (DSA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Regression degree of DSA;Visual analogue scale(VAS);Micro-ultrasound imaging;Lesions temperature;Lesions color; | — |
Countries
China
Contacts
Public ContactXiaoxi Lin
Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed